APA (7th ed.) Citation

MP, J., J, K., CN, P., SM, M., PK, T., KA, C., . . . A, P. (2025). Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia : an international journal of headache, 45(8), 3331024251368757. https://doi.org/10.1177/03331024251368757

Chicago Style (17th ed.) Citation

MP, Johnson, et al. "Preclinical and Clinical Evaluation of LY3451838, a PACAP-neutralizing Monoclonal Antibody, in Randomized, Double-blind, Placebo-controlled Phase 1 and Phase 2 Studies Involving Healthy Adults and Adults with Treatment-resistant Migraine." Cephalalgia : An International Journal of Headache 45, no. 8 (2025): 3331024251368757. https://doi.org/10.1177/03331024251368757.

MLA (9th ed.) Citation

MP, Johnson, et al. "Preclinical and Clinical Evaluation of LY3451838, a PACAP-neutralizing Monoclonal Antibody, in Randomized, Double-blind, Placebo-controlled Phase 1 and Phase 2 Studies Involving Healthy Adults and Adults with Treatment-resistant Migraine." Cephalalgia : An International Journal of Headache, vol. 45, no. 8, 2025, p. 3331024251368757, https://doi.org/10.1177/03331024251368757.